Clopidogrel Use and Hospital Quality in Medically Managed Patients With Non ST-Segment Elevation Myocardial Infarction
|
|
- Andrew O’Brien’
- 5 years ago
- Views:
Transcription
1 Clopidogrel Use and Hospital Quality in Medically Managed Patients With Non ST-Segment Elevation Myocardial Infarction Thomas M. Maddox, MD, MSc; P. Michael Ho, MD, PhD; Thomas T. Tsai, MD, MSc; Tracy Y. Wang, MD, MHS, MSc; Shuang Li, MS; S. Andrew Peng, MS; Stephen D. Wiviott, MD; Fredrick A. Masoudi, MD, MSPH; John S. Rumsfeld, MD, PhD Background Clopidogrel prescription is a class I guideline recommendation for medically managed patients with non ST-segment elevation myocardial infarction (NSTEMI). However, clopidogrel has historically been underused in this population. We evaluated contemporary rates of its use and evaluated associated factors, with a particular focus on hospital quality of myocardial infarction (MI) care. Methods and Results We examined clopidogrel prescription rates among patients with NSTEMI discharged from 382 US hospitals between October 2009 and March Associations between clopidogrel prescription and various patient and hospital factors, including hospital quality of MI care, were determined with regression modeling. Of the sample, 54.9% of eligible patients with NSTEMI received clopidogrel prescription at hospital discharge. Variation in rate by hospital was large, ranging from 22% to 97%. A variety of patient and hospital factors were associated with clopidogrel prescription. Hospital quality of MI care demonstrated modest association with clopidogrel prescription (odds ratio, 0.68; 95% CI, ) between the lowest and highest hospital quality quartile) and accounted for 5.7% of the variation in prescription rates. Conclusions Clopidogrel prescription is significantly underused in the medically managed NSTEMI population and demonstrates wide variability by hospital. Although hospital quality of MI care is associated with its use, the findings suggest that it only has a modest effect. Therefore, efforts to improve clopidogrel use likely will require measures beyond improving the overall hospital quality of MI care. (Circ Cardiovasc Qual Outcomes. 2012;5:00-00.) Key Words: myocardial infarction prevention coronary artery disease In the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, antiplatelet therapy with clopidogrel and aspirin was associated with an improved 1-year primary outcome of cardiovascular death, nonfatal myocardial infarction (MI), or stroke among patients with non ST-segment elevation myocardial infarction (NSTEMI) compared with aspirin alone. 1 This treatment benefit was similar among revascularized patients and those managed medically. Accordingly, clopidogrel prescription for all patients with NSTEMI at hospital discharge is a class I recommendation in the most recent American College of Cardiology/American Heart Association (ACC/AHA) guidelines. 2 In addition, clopidogrel prescription at discharge for patients with NSTEMI was added as a test measure in the recently updated ACC/AHA performance measures for acute MI (AMI) care. 3 Despite these measures, clopidogrel use among the medically managed NSTEMI population is suboptimal, with more than one half of these patients failing to receive its prescription at hospital discharge. 4 This gap in care represents a target for quality improvement. Understanding factors associated with this gap can inform efforts to improve current prescription practices of clopidogrel. In addition, these insights may inform optimal dissemination of the newer antiplatelet therapies, such as prasugrel and ticagrelor, among medically managed patients with acute coronary syndrome. Accordingly, we assessed clopidogrel prescription rates and their variation by hospital in a large national clinical registry of patients with NSTEMI. We then determined patient and hospital factors associated with clopidogrel pre- Received August 30, 2011; accepted April 16, From the VA Eastern Colorado Health Care System, Denver, CO (T.M.M., P.M.H., T.T.T., J.S.R.); University of Colorado Denver, Aurora, CO (T.M.M., P.M.H., T.T.T., F.A.M.); Duke Clinical Research Institute, Durham, NC (T.Y.W., S.L., S.A.P.); and TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medicine School, Boston, MA (S.D.W.). Drs Masoudi and Rumsfeld, Associate Editors of Circulation: Quality and Outcomes, are coauthors of the article but had no role in the evaluation of the article or the decision about its acceptance. This article was handled independently by Guest Editor David J. Moliterno, MD. Correspondence to Thomas M. Maddox, MD, VA Eastern Colorado Health Care System; Cardiology (111B), 1055 Clermont St; Denver, CO thomas.maddox@va.gov 2012 American Heart Association, Inc. Circ Cardiovasc Qual Outcomes is available at DOI: /CIRCOUTCOMES Downloaded from 1 by guest on May 12, 2016
2 2 Circ Cardiovasc Qual Outcomes July 2012 scription, with a particular focus on overall hospital quality of AMI care. By providing a better understanding of these relationships, we can inform quality improvement initiatives to improve clopidogrel prescription rates. WHAT IS KNOWN Clopidogrel, in conjunction with aspirin, significantly reduces the rate of recurrent cardiac events and mortality among medically managed patients with myocardial infarction. However, clopidogrel has been consistently underused in this population. WHAT THE STUDY ADDS In a contemporary, national sample of cardiac patients, only 54.9% of eligible patients with non ST-segment elevation myocardial infarction were discharged from the hospital with a clopidogrel prescription. There was significant variation in clopidogrel discharge rates by hospital, ranging from 22% to 97%. Hospital performance on quality-of-care measures for patients with myocardial infarction was modestly associated with clopidogrel prescription rates and accounted for only 5.7% of the variation in these rates. Methods Study Population We evaluated patients in the National Cardiovascular Data Registry s (NCDR s) Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines (ACTION Registry-GWTG). The registry records patient and treatment characteristics of individuals with MI hospitalized in a variety of practice settings throughout the United States. 5 Trained abstractors at each site collect patient, presentation, treatment, and hospital characteristics from the medical record in a standardized fashion. Once the registry receives the data, the data undergo extensive quality review with required completeness standards, logic checks, and onsite data accuracy audits. Only data meeting these data quality standards are included in the research registry. Analyses are conducted at the ACTION Registry-GWTG analytic center located at the Duke Clinical Research Institute (Durham, NC). Full details of the registry are located at Study Cohort In this study, we evaluated patients with NSTEMI who were medically managed without percutaneous or surgical revascularization. We focused on patients with NSTEMI both because of the recent addition of the clopidogrel test performance measure for medically treated patients with MI and because patients with ST-segment elevation MI have high rates of percutaneous coronary intervention treatment and clopidogrel use. Exclusion criteria included patients who had a documented contraindication to clopidogrel, died during hospitalization, were transferred to a different facility, were discharged on comfort measures or to hospice, left against medical advice, had missing discharge clopidogrel information, or were discharged on ticlopidine or prasugrel. Figure 1. Study cohort creation. NSTEMI indicates non ST-segment elevation myocardial infarction. Variables The primary dependent (outcome) variable of interest was clopidogrel prescription at hospital discharge as recorded from the ACTION Registry-GWTG case report form containing the abstracted patient chart list of discharge medications. Independent variables of interest were selected on the basis of prior studies and clinical judgment and included demographic, clinical history, presentation and treatment, and hospital factors. Demographic factors included age (per 10-year increase), sex, race (white versus other), and insurance type (health maintenance organization versus government versus self-pay or none). Clinical history factors included prior MI, prior percutaneous coronary intervention, prior coronary artery bypass graft, peripheral arterial disease (PAD), cerebrovascular disease, diabetes mellitus, hypertension, hyperlipidemia, smoking, body mass index per 5-kg/m 2 increase, renal failure requiring dialysis, and medications before admission (aspirin, -blockers, statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, clopidogrel, and warfarin). Presentation and treatment factors included admission heart rate (per 100-beats/min increase), admission blood pressure (per 10-mm Hg increase), admission renal function (categorized as creatinine clearance 60 ml/min, ml/min, and 30 ml/min), admission hematocrit level (categorized as 30% versus 30%), ejection fraction (EF) (categorized as 40% versus 40%), troponin level (categorized as 3 times the upper limit of normal of the assay measurement versus 3 times the upper limit of normal), receipt of diagnostic catheterization during hospitalization, and in-hospital major and minor bleeding (see later for definitions). Hospital factors included number of beds (per 100-bed increase); presence of diagnostic catheterization, percutaneous coronary intervention, and cardiothoracic surgical service facilities; teaching hospital (versus community hospital), and overall hospital quality of MI care (see later for definition). In-hospital major bleeding was defined as an absolute hematocrit drop in level of 12%, an intracranial hemorrhage, a retroperitoneal bleed, an admission hematocrit level of 28% plus a red blood cell transfusion, or an admission hematocrit level of 28% plus a red blood cell transfusion and a witnessed bleeding event. Minor bleeding was defined as a suspected bleeding event that did not meet a major bleeding criterion. Hospital quality of MI care was defined as the percentage of fulfilled quality opportunities for each hospital, as suggested by the Joint Commission. 6 Quality opportunities were based on the 2008 ACC/AHA AMI performance measures, which did not include clopidogrel prescription at discharge. 3 They included aspirin administration within 24 hours of arrival, aspirin prescription at discharge, -blocker prescription at discharge, statin prescription at discharge, evaluation of EF before discharge, angiotensin-converting enzyme
3 Maddox et al Clopidogrel and Hospital Quality 3 Table 1. Baseline Characteristics for Patients Discharged With or Without Clopidogrel Prescription Clopidogrel at Discharge (n ) No Clopidogrel at Discharge (n ) P Value Patient factors Age, y 71 (60 82) 72 (60 83) Male sex 6730 (53.9) 5332 (49.9) White race 9987 (80.0) 8318 (77.8) Insurance HMO 6780 (54.3) 5655 (52.9) Government 4929 (39.5) 4200 (39.3) Self, none, missing 781 (6.3) 841 (7.9) Clinical history factors Prior MI 5185 (41.5) 2845 (26.6) Prior PCI 4444 (35.6) 1658 (15.5) Prior CABG 3846 (30.8) 2044 (19.1) PAD 2309 (18.5) 1325 (12.4) CVD 1770 (14.2) 1341 (12.5) Diabetes 5406 (43.3) 3848 (36.0) HTN (85.3) 8617 (80.6) Dyslipidemia 8920 (71.4) 6306 (59.0) Current/recent smoker 2996 (24.0) 2394 (22.4) BMI, kg/m ( ) 27.4 ( ) Renal failure requiring dialysis 542 (4.3) 434 (4.1) 0.28 Home aspirin 7424 (59.4) 4931 (46.1) Home -blocker 7235 (57.9) 4976 (46.5) Home statin 7103 (56.9) 4596 (43.0) Home ACEI 4722 (37.8) 3522 (32.9) Home ARB 1724 (13.8) 1309 (12.2) Home clopidogrel 5031 (40.3) 325 (3.0) Home warfarin 613 (4.9) 1479 (13.8) Presentation and treatment factors Admission HR, beats/min 85 (72 100) 89 (75 107) Admission systolic BP, mm Hg 147 ( ) 143 ( ) Admission renal function, Cockcroft-Gault (51.0) 5074 (49.4) 30, (34.7) 3597 (35.1) (13.5) 1524 (14.9) Admission Hgb 9 g/dl 368 (3.0) 541 (5.1) Ejection fraction 40% 2722 (24.0) 2415 (25.0) 0.11 Troponin 3 ULN (85.6) 8757 (81.9) Diagnostic catheterization during hospitalization 7537 (60.3) 5966 (55.8) In-hospital major bleeding 910 (7.3) 1028 (9.6) Suspected bleeding event 272 (2.2) 343 (3.2) Hospital factors No. hospital beds 395 ( ) 384 ( ) Hospital facilities 0.03 No catheterization laboratory 182 (1.5) 197 (1.8) Diagnostic catheterization only 284 (2.3) 278 (2.6) PCI without cardiothoracic surgery 928 (7.4) 758 (7.1) PCI and cardiothoracic surgery (88.8) 9463 (88.5) Teaching hospital 3154 (25.3) 2528 (23.6) Delivery of quality measures Quartile 1 ( 96%) 3757 (30.1) 2671 (25.0) Quartile 2 (92% 96%) 3465 (27.7) 2871 (26.8) Quartile 3 (86% 91%) 3078 (24.6) 2972 (27.8) Quartile 4 (53% 85%) 2105 (16.9) 2117 (19.8) Data are presented as median (25th 75th percentile) or n (%). HMO indicates health maintenance organization; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; PAD, peripheral arterial disease; CVD, cerebrovascular disease; HTN, hypertension; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HR, heart rate; BP, blood pressure; Hgb, hemoglobin; ULN, upper limit of normal.
4 4 Circ Cardiovasc Qual Outcomes July 2012 Figure 2. Rates of clopidogrel prescription by hospital quality quartile of quality opportunities fulfilled (quartile 1, 93%; quartile 2, 87% 93%; quartile 3, 80% 86%; quartile 4, 80%). inhibitor/angiotensin receptor blocker prescription for patients with an EF 40%, smoking cessation counseling provided for current smokers, and cardiac rehabilitation referral at discharge. Hospital quality was then calculated by dividing the number of these quality measures that occurred by the number of quality opportunities that the hospital had to provide quality MI care. After these calculations were performed, hospitals were categorized by quartile of quality performance (quartile 1, highest quality; quartile 4, lowest quality). Statistical Analysis Rates of clopidogrel prescription for the overall cohort and by hospital were calculated. The cohort was then stratified by clopidogrel prescription at hospital discharge, and we compared demographic, clinical history, presentation, treatment, and hospital factors. Continuous variables are presented as medians and compared using either t tests or Wilcoxon rank sum tests, depending on the normality of the data distribution. Categorical variables were presented as percentages and compared with 2 tests. For the hospital rates, only those hospitals treating 30 patients were included to ensure stable estimates. Observed rates of clopidogrel prescription by hospital were calculated, and exact 95% binomial CIs were generated. To determine associations of the various patient and hospital factors with the likelihood of clopidogrel prescription, we specified multivariable logistic regression models using generalized estimating equations to control for clustering of patients by hospital. To properly specify the models, patients who were treated at hospitals that contributed 30 patients to the ACTION Registry-GWTG or who were treated at hospitals with missing hospital data were excluded from analysis. A C statistic for the full model was calculated to determine its discriminatory ability. To understand the relationship between hospital quality of MI care and hospital rates of clopidogrel, we generated a scatterplot of these 2 measures and calculated a Pearson correlation coefficient to determine the correlation between the 2 variables. We also calculated the R 2 variable to determine the amount of clopidogrel prescription variation that could be explained by variation in hospital quality of MI care. Because clopidogrel use before MI admission was strongly associated with clopidogrel prescription at discharge, we conducted a secondary analysis removing those patients from the analysis to explore factors associated with clopidogrel prescription among those without prior use. Similarly, because warfarin use before admission was strongly associated with a lack of clopidogrel prescription at discharge (likely because of the uncertainty and risks surrounding triple therapy), we also excluded those patients from the secondary analysis. Thus, the cohort for the secondary analysis comprised patients without clopidogrel or warfarin use on admission. Finally, because providers may restrict their use of clopidogrel only to those patients who would have qualified for inclusion in the CURE trial, we conducted a secondary analysis excluding those patients from the present primary study cohort who would have been excluded from the CURE trial. 1 Our exclusion criteria were patient contraindication to antiplatelets or anticoagulants, patients with a suspected bleeding event or hemorrhagic cerebrovascular accident, patients with heart failure or shock on presentation or during hospitalization, and patients on home or discharge warfarin. Similar to our primary analysis, rates of clopidogrel prescription and predictors of its use in this cohort were calculated. For all analyses, P 0.05 was considered significant. All analyses were performed using SAS version 10 (SAS Institute) statistical software. Results Rates of Clopidogrel Prescription at Discharge Between October 2009 and March 2011, medically managed patients with NSTEMI at 387 hospitals were rec- Figure 3. Rates of clopidogrel prescription by hospital.
5 Maddox et al Clopidogrel and Hospital Quality 5 orded in the ACTION Registry-GWTG. After applying our exclusion criteria, at 382 hospitals remained in the study cohort (Figure 1). In the study cohort, (53.9%) patients received a clopidogrel prescription at hospital discharge. Table 1 lists the patient and hospital factors by receipt of clopidogrel prescription at discharge. Among demographic factors, younger age, male sex, white race, and the presence of health maintenance organization or government insurance were associated with higher rates of clopidogrel prescription. Among clinical history factors, higher rates of prior cardiovascular disease, cardiac risk factors, and cardiac medication use before hospital admission for MI were associated with higher rates of clopidogrel prescription. The sole exception was warfarin use before admission, where higher rates of its use were associated with lower rates of clopidogrel prescription. Among treatment factors, higher rates of diagnostic catheterization and lower rates of in-hospital bleeding were associated with higher rates of prescription. Among hospital factors, hospitals with catheterization laboratories or with higher quality of MI care were associated with higher rates of clopidogrel prescription. Figure 2 illustrates the differences in clopidogrel prescription rates as a function of hospital quality of MI care. To calculate hospital rates of clopidogrel prescription, we excluded 141 hospitals with 30 patients (total number of patients excluded, 2 101). Among this cohort of 241 hospitals, rates of clopidogrel prescription varied widely, ranging from 22% to 97% (Figure 3). Table 2. Factors Associated With Clopidogrel Prescription at Discharge 2 OR (95% CI) Demographic factors White race ( ) Clinical history factors Dyslipidemia ( ) Diabetes ( ) Current/recent smoker ( ) Prior MI ( ) Prior PCI ( ) Prior CABG ( ) PAD ( ) Home clopidogrel ( ) Home warfarin ( ) Presentation and treatment factors Admission systolic BP (per ( ) 10-mm Hg increase) Diagnostic catheterization ( ) Troponin 3 ULN ( ) Admission HR (per 10-beats/min ( ) increase) Admission Hgb 9 g/dl ( ) Ejection fraction 40% ( ) In-hospital major bleeding ( ) Hospital factors Delivery of quality measures (relative to quartile 1 96% ) Quartile 2 (92% 96%) 0.83 ( ) Quartile 3 (86% 91%) 0.7 ( ) Quartile 4 (53% 85%) 0.68 ( ) OR indicates odds ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; PAD, peripheral arterial disease; BP, blood pressure; ULN, upper limit of normal; HR, heart rate; Hgb, hemoglobin. Associations Between Patient and Hospital Factors and Clopidogrel Prescription After exclusion of 150 patients with missing hospital data or treated at hospitals with 30 ACTION Registry-GWTG patients, patients treated at 350 hospitals were included in the primary multivariable model. A variety of factors were associated with clopidogrel prescription at discharge (Table 2). The only demographic factor associated with higher rates of clopidogrel prescription was white race. Among clinical history factors, dyslipidemia, diabetes, current or recent smoking, prior coronary artery disease (indicated by prior MI, percutaneous coronary intervention, or coronary artery bypass graft), PAD, and clopidogrel use before admission were associated with higher rates of clopidogrel prescription, whereas warfarin use before admission was associated with lower rates. Among presentation and treatment factors, higher admission blood pressure, receipt of diagnostic catheterization, and higher troponin values were associated with higher rates of clopidogrel prescription, whereas higher admission heart rate, admission hemoglobin level of 9 g/dl, EF of 40%, and in-hospital major bleeding were associated with lower rates of clopidogrel prescription. Among hospital factors, quality of MI care significantly affected clopidogrel prescription rates. Patients treated at a hospital in the lowest quartile of quality performance, relative to hospitals in the highest quartile, had 32% lower odds to receive clopidogrel prescription (odds ratio, 0.68; 95% CI, ) (Table 2). The full model demonstrated good discrimination between those with and those without clopidogrel prescription (C statistic, 0.78). There was a modest positive correlation between hospital quality of MI care and hospital-level clopidogrel prescription rates (Pearson correlation coefficient, 0.24; P ) (Figure 4). The R 2 value between the 2 factors was 0.057, meaning that 5.7% of the variation in the clopidogrel prescription rates was explained by variation in hospital quality of MI care. Results of our secondary analysis, which excluded patients taking clopidogrel or warfarin before hospital admission (n 5356 and n 1789, respectively) are shown in Table 3. In contrast to the primary analysis, significant associations with clopidogrel prescription and older age, male sex, and larger hospitals were seen, and associations with diabetes and PAD were no longer present. Results of the secondary analysis replicating the CURE trial are shown in Table 4. Among the subset of patients who closely resembled trial participants, rates of clopidogrel prescription at discharge increased to 58.8%. As with the other secondary analysis, significant
6 6 Circ Cardiovasc Qual Outcomes July 2012 Figure 4. Scatterplot of hospital quality of myocardial infarction care and clopidogrel prescription at discharge rates. associations with clopidogrel prescription and older age, male sex, and larger hospitals were seen. In addition, associations with diabetes, smoking, PAD, and an EF of 40% were no longer present. Discussion In this large national cohort of medically managed patients with NSTEMI, only 56% of eligible patients received clopidogrel prescription at discharge, with wide variability in rates of prescription by hospital. Patient-level factors such as male sex, white race, cardiac risk factors, receipt of diagnostic catheterization, treatment by a cardiologist, and higher troponin levels were associated with higher prescription rates. Other patient-level factors such as anemia, in-hospital bleeding events, and warfarin use before admission were associated with lower rates of clopidogrel prescription. Among hospital-level factors, higher quality of MI care was associated with higher rates of clopidogrel prescription, although this relationship was only modest. Furthermore, the variation in hospital quality of MI care only explained 12% of the variation in clopidogrel prescription rates. Among patients who resembled the CURE trial population, the rates of clopidogrel were higher (58.8%), but still suboptimal. These findings demonstrate a significant gap in clopidogrel prescription to medically managed patients with NSTEMI and a wide variability in prescription rates by hospital and suggest that other measures beyond focusing on overall hospital quality of MI care are needed to improve clopidogrel prescription rates. Based on the CURE trial, clopidogrel prescription at discharge is a class I guideline and is currently a test performance measure for AMI care. 1 3 However, the uptake of clopidogrel in routine clinical practice for patients with NSTEMI has been suboptimal. Tricoci and colleagues 7 examined patients with NSTEMI eligible for clopidogrel prescription from 461 hospitals between January 2002 and December 2003 in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) Registry, which was a precursor to the NCDR ACTION Registry-GWTG. They demonstrated that only 42.8% of medically managed patients received clopidogrel prescription at discharge. Amsterdam and colleagues, 4 who also used CRUSADE data, showed that prescription rates among the medically managed NSTEMI population increased to 53.9% by The present study finds that there has been little change in these rates for medically managed patients with NSTEMI, despite the guideline and performance measure emphasis on this metric. Why has clopidogrel use remained practically unchanged for the medically managed NSTEMI population? The present study suggests that multiple factors are at play, including several that may be targets for quality improvement. Clopidogrel prescription, like any medication or therapy, requires evaluation of its benefits and risks to the individual patient. Accordingly, factors that confer higher cardiac risk, such as dyslipidemia, diabetes, prior revascularization, PAD, and higher troponin levels may influence providers to prescribe clopidogrel to minimize this risk. Similarly, factors that confer a higher risk of bleeding, such as hemodialysis, anemia, concurrent warfarin use, or major bleeding during hospitalization, may prohibitively increase the risk of clopidogrel therapy, thus influencing providers to avoid clopidogrel prescription. The association between receipt of diagnostic catheterization and higher rates of clopidogrel has been demonstrated previously 4 and may represent more cardiology involvement during hospitalization, with a subsequent focus on optimal cardiac therapies, and may reflect selection of patients believed to have a more optimal risk/treatment benefit for clopidogrel therapy. Similarly, the relationship between cardiologist care and higher rates of evidence-based cardiac therapies, including clopidogrel, is a well-studied association and likely demonstrates cardiologists greater familiarity and comfort with cardiac therapies as well as some selection bias in which patients receive cardiology care. 7,8 Finally, disparities of treatment by sex and race persist, a troubling trend that
7 Maddox et al Clopidogrel and Hospital Quality 7 Table 3. Factors Associated With Clopidogrel Prescription Among Patients Without Clopidogrel or Warfarin Use Before Admission 2 OR (95% CI) Demographic factors Age (per 10-y increase) ( ) Male sex ( ) White race ( ) Clinical history factors Dyslipidemia ( ) Current or recent smoker ( ) Prior MI ( ) Prior PCI ( ) Prior CABG ( ) Presentation and treatment factors Admission systolic BP (per ( ) 10-mm Hg increase) Diagnostic catheterization ( ) Troponin 3 ULN ( ) Admission HR (per 10-beats/min ( ) increase) Admission Hgb 9 g/dl ( ) Ejection fraction 40% ( ) In-hospital major bleeding ( ) Hospital factors No. of hospital beds (per 100) ( ) Delivery of quality measures (relative to quartile 1 96% ) Quartile 2 (92% 96%) 0.79 ( ) Quartile 3 (86% 91%) 0.72 ( ) Quartile 4 (53% 85%) 0.65 ( ) OR indicates odds ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; BP, blood pressure; ULN, upper limit of normal; HR, heart rate; Hgb, hemoglobin. Table 4. Factors Associated With Clopidogrel Prescription Among Patients Without CURE Exclusion Criteria 2 OR (95% CI) Demographic factors Age (per 10-y increase) ( ) Male sex ( ) White race ( ) Clinical history factors Dyslipidemia ( ) Prior MI ( ) Prior PCI ( ) Prior CABG ( ) Home clopidogrel ( ) Presentation and treatment factors Admission systolic BP (per ( ) 10-mm Hg increase) Diagnostic catheterization ( ) Troponin 3 ULN ( ) Admission HR (per 10-beats/min ( ) increase) Admission Hgb 9 g/dl ( ) In-hospital major bleeding ( ) Hospital factors No. of hospital beds (per 100) ( ) Delivery of quality measures (relative to quartile 1 96% ) Quartile 2 (92% 96%) 0.8 ( ) Quartile 3 (86% 91%) 0.71 ( ) Quartile 4 (53% 85%) 0.68 ( ) CURE indicates Clopidogrel in Unstable Angina to Prevent Recurrent Events; OR, odds ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; BP, blood pressure; ULN, upper limit of normal; HR, heart rate; Hgb, hemoglobin. has been demonstrated in prior studies 9 and warrants further investigation. How can rates of clopidogrel prescription be improved? The positive correlation between hospital quality of MI care and clopidogrel prescription rates is encouraging, but the low R 2 value between the 2 factors indicates that simply improving overall hospital quality of MI care would have little effect on improving clopidogrel prescription. Rather, a more successful approach may be the incorporation of clopidogrel prescription as a performance measure for hospitals. The 2008 MI performance measures, released after the dates of the present study, included clopidogrel prescription rates for this population as a test measure, indicating that the writing committee believed that this measure was appropriate for internal quality improvement measures but not for external reporting until further validation and testing could be performed. 3 Future studies should investigate the impact of this test measure designation on reducing hospital variation in clopidogrel prescription rates. If significant improvement has not occurred and further studies can demonstrate reduction in death and recurrent MI, specifically among contemporary, medically managed patients with NSTEMI treated with clopidogrel, then consideration should be given to making clopidogrel prescription rates a full performance measure to provide external pressure to improve rates. Insights into factors associated with clopidogrel prescription can also inform the emerging use of the newer antiplatelet therapies prasugrel and ticagrelor because both have demonstrated salutary effects on patients with acute coronary syndromes and are likely to become part of routine clinical practice. Prasugrel is currently being compared with clopidogrel for medically managed patients with acute coronary syndromes in the TRILOGY-ACS (A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed) trial. 10 Ticagrelor demonstrated greater efficacy than clopidogrel for medically managed patients with NSTEMI in the PLATO (Platelet Inhibition and Patient Outcomes) trial, and recently received Food and Drug Administration approval for treatment in this population. 11,12 As these agents make the transition from clinical trials to the real world, the factors that affect clopidogrel prescription are also likely to affect their use, suggesting that quality improvement initiatives are likely to
8 8 Circ Cardiovasc Qual Outcomes July 2012 benefit prescription rates of all agents. Furthermore, despite the emergence of these newer agents, clopidogrel would be expected to remain a mainstay of antiplatelet therapy for patients with MI given the long-term experience with its use and its lower cost. The present study has several limitations. First, the ACTION Registry-GWTG only records prescription rates and does not track actual fill and use rates of the medication. Furthermore, the registry does not track care after discharge. However, prior studies have demonstrated that gaps in both prescription and use of secondary prevention medications, such as clopidogrel, at hospital discharge, are often magnified rather than reduced in the outpatient setting. 13,14 Second, incomplete or inaccurate documentation of clopidogrel contraindication could cause our characterization of a gap to be overstated. However, data abstraction for the ACTION Registry-GWTG is subject to data quality methods, which minimizes this potential bias. Third, the ACTION Registry- GWTG does not contain granular information on hospital quality processes. Thus, the general associations illustrated in this study will need confirmation and exploration among individual hospitals and delivery systems to identify specific hospital and provider factors that contribute to this gap. Fourth, the ACTION Registry-GWTG is an observational cohort and, thus, subject to unmeasured variables that may confound the reported associations. However, the size of the data set combined with robust modeling techniques that include multiple covariates for clopidogrel use reduces this source of error. Nonetheless, residual confounding can never be fully eliminated, and this may affect the findings. Fifth, the CURE trial took place 10 years ago. More contemporary treatments (eg, early invasive catheterization and intervention) may lessen the impact of the benefit of clopidogrel among the current NSTEMI population. Accordingly, providers may be appropriately deciding that the benefit of clopidogrel does not justify its risks. The data did not capture the nuances of this clinical consideration. Finally, participation in the ACTION Registry-GWTG is voluntary and likely represents hospitals delivering higher-quality care. Thus, the findings likely underreport the true extent of clopidogrel underuse in US hospitals. In conclusion, we found that significant gaps in clopidogrel prescription among medically managed patients with NSTEMI persist in contemporary practice, despite clinical practice guideline recommendations and the inclusion of clopidogrel prescription as a test performance measure for AMI. Clopidogrel prescription rates vary widely by hospital and are associated with a variety of patient and hospital factors. Although hospital quality of MI care is associated with its use, the present findings suggest that it only has a modest effect. Thus, other measures beyond improving the overall hospital quality of MI care, such as directly assessing clopidogrel prescription as a quality measure, are necessary to improve clopidogrel prescription rates and reduce adverse outcomes among medically managed patients with NSTEMI. Acknowledgments Dr Maddox is supported by a Veterans Administration Health Services Research and Development Career Development Award. He had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This research was supported by the ACC Foundation s NCDR. The views expressed in this article represent those of the authors and do not necessarily represent the official views of the NCDR or its associated professional societies identified at Sources of Funding ACTION Registry-GWTG is an initiative of the ACC Foundation and the AHA with partnering support from the Society of Chest Pain Centers, the American College of Emergency Physicians, and the Society of Hospital Medicine. The registry is funded in part by an independent grant from Merck and by Bristol-Myers Squibb (who manufacture clopidogrel). The sponsors had no role in the conception, design, analysis, or writing of this article. None. Disclosures References 1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345: Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non- ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1 e Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, Ho PM, Kosiborod MN, Masoudi FA, Nallamothu BK. ACC/AHA 2008 performance measures for adults with ST-elevation and non-st-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American Academy of Family Physicians and American College of Emergency Physicians endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol. 2008;52: Amsterdam EA, Peterson ED, Ou F-S, Newby LK, Pollack CV, Gibler WB, Ohman EM, Roe MT. Comparative trends in guidelines adherence among patients with non-st-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: results from the CRUSADE quality improvement initiative. Am Heart J. 2009;158: Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, Roe MT. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With The Guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011; 161: Kahn CN III, Ault T, Isenstein H, Potetz L, Van Gelder S. Snapshot of hospital quality reporting and pay-for-performance under Medicare. Health Aff (Millwood). 2006;25: Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC, Pollack CV, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-st-segment elevation
9 Maddox et al Clopidogrel and Hospital Quality 9 acute coronary syndromes after hospital discharge. Arch Intern Med. 2006;166: Ho PM, Luther SA, Masoudi FA, Gupta I, Lowy E, Maynard C, Sales AE, Peterson ED, Fihn SD, Rumsfeld JS. Inpatient and follow-up cardiology care and mortality for acute coronary syndrome patients in the Veterans Health Administration. Am Heart J. 2007;154: Chan MY, Becker RC, Harrington RA, Peterson ED, Armstrong PW, White H, Fox KAA, Ohman EM, Roe MT. Noninvasive, medical management for non-st-elevation acute coronary syndromes. Am Heart J. 2008;155: Chin CT, Roe MT, Fox KAA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-st-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010;160: Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357: Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361: Ho PM, Tsai TT, Maddox TM, Powers JD, Carroll NM, Jackevicius C, Go AS, Margolis KL, DeFor TA, Rumsfeld JS, Magid DJ. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes. 2010;3: Ho PM, Tsai TT, Wang TY, Shetterly SM, Clarke CL, Go AS, Sedrakyan A, Rumsfeld JS, Peterson ED, Magid DJ. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes. 2010;3:
10 Clopidogrel Use and Hospital Quality in Medically Managed Patients With Non ST-Segment Elevation Myocardial Infarction Thomas M. Maddox, P. Michael Ho, Thomas T. Tsai, Tracy Y. Wang, Shuang Li, S. Andrew Peng, Stephen D. Wiviott, Fredrick A. Masoudi and John S. Rumsfeld Circ Cardiovasc Qual Outcomes. published online May 8, 2012; Circulation: Cardiovascular Quality and Outcomes is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX Copyright 2012 American Heart Association, Inc. All rights reserved. Print ISSN: Online ISSN: The online version of this article, along with updated information and services, is located on the World Wide Web at: Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
Clopidogrel Use and Hospital Quality in Medically Managed Patients With Non ST-Segment Elevation Myocardial Infarction
Clopidogrel Use and Hospital Quality in Medically Managed Patients With Non ST-Segment Elevation Myocardial Infarction Thomas M. Maddox, MD, MSc; P. Michael Ho, MD, PhD; Thomas T. Tsai, MD, MSc; Tracy
More informationOriginal Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice
Am J Cardiovasc Dis 2012;2(3):248-252 www.ajcd.us /ISSN:2160-200X/AJCD1204002 Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Angela
More informationOP Chest Pain General Data Element List. All Records All Records. All Records All Records All Records. All Records. All Records.
Material inside brackets ([and]) is new to this Specifications Manual version. Hospital Outpatient Quality Measures Chest Pain (CP) Set Measure ID # OP-4 * OP-5 * Measure Short Name Aspirin at Arrival
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Measure Set: Acute Myocardial Infarction (AMI) Set Measure ID#: Performance Measure Name:
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationConsensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationTAB 7: SUB TAB: AMI/CHEST PAIN Specifications & Paper Tools
TAB 7: SUB TAB: AMI/CHEST PAIN Specifications & Paper Tools Material inside brackets ([and]) is new to this Specifications Manual version. Hospital Outpatient Quality Measures Acute Myocardial Infarction
More informationUse of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 11, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.08.015 CLINICAL RESEARCH
More informationAntithrombotic Strategy in Non ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 6, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.03.015 Antithrombotic
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationUtilization and Impact of Pre-Hospital Electrocardiograms for Patients With Acute ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 53, No. 2, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.030
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationVersion 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM
Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute
More informationAcute coronary syndromes (ACS), including unstable
n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction
More informationJournal of the American College of Cardiology Vol. 45, No. 6, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 6, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.11.055
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationKnow the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium
Know the Quality of our Care at Every Step Kansas City ACS Summit BI-State Cardiovascular Education Consortium Welcome to the Kansas City ACS Summit Objectives: Follow the flow and care of an ACS patient
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationAtrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes
CLINICAL RESEARCH STUDY Atrial and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes Renato D. Lopes, MD, PhD, a Li Li, MS, a Christopher B. Granger, MD, a Tracy Y. Wang, MD, MHS, MSc, a
More informationThe Evolving ACC-NCDR Programs: What you need to know for your practice
The Evolving ACC-NCDR Programs: What you need to know for your practice John S. Rumsfeld, MD PhD FACC Chief Science Officer and Chair, American College of Cardiology National Cardiovascular Data Registry
More informationAntiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital
Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Authors G. Mason*, F. Wirth**, A. Cignarella***, R.G. Xuereb****, L.M. Azzopardi***** *Final Year
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationClinical Investigations
Clinical Investigations The Usage Patterns of Cardiac Bedside Markers Employing Point-of-Care Testing for Troponin in Non-ST-Segment Elevation Acute Coronary Syndrome: Results from CRUSADE Address for
More informationSecondary prevention therapies are indicated for patients
Utilization of Secondary Prevention Therapies in Patients With Nonobstructive Coronary Artery Disease Identified During Cardiac Catheterization Insights From the National Cardiovascular Data Registry Cath-PCI
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationMeasurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationAffordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA presenting on behalf of ARTEMIS Investigators Guidelines DAPT
More informationORIGINAL INVESTIGATION. Clopidogrel to Treat Patients With Non ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge
ORIGINAL INVESTIGATION to Treat Patients With Non ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge Pierluigi Tricoci, MD; Matthew T. Roe, MD, MHS; Jyotsna Mulgund, MS; L. Kristin
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationTHE BRIDGE-ACS TRIAL
A Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of Acute Coronary Syndromes: THE BRIDGE-ACS TRIAL Presenter: Otavio Berwanger (MD; PhD) on Behalf of the BRIDGE-ACS Steering
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationOvercoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD
Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationTransfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem
Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927
More informationSupplementary Online Content
Supplementary Online Content Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand S-LT, Rumsfeld JS, Messenger JC, Yeh RW. Use of
More informationThe Impact of For-Profit Hospital Status on the Care and Outcomes of Patients With Non ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 50, No. 15, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.012
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationCoronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study
Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationORIGINAL INVESTIGATION. Recent Trends in the Care of Patients With Non ST-Segment Elevation Acute Coronary Syndromes
ORIGINAL INVESTIGATION Recent Trends in the Care of Patients With Non ST-Segment Elevation Acute Coronary Syndromes Insights From the CRUSADE Initiative Rajendra H. Mehta, MD, MS; Matthew T. Roe, MD, MHS;
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationINTRODUCTION. Key Words:
Original Article Acta Cardiol Sin 2017;33:377 383 doi: 10.6515/ACS20170126A Percutaneous Coronary Intervention Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome
More informationNews the. Methods Data collection. The NCDR is a national registry of patients undergoing diagnostic cardiac catheterizations
Journal of the American College of Cardiology Vol. 52, No. 20, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.017
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationAssociation Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes JAMA. 2006;295:
ORIGINAL CONTRIBUTION Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes Eric D. Peterson, MD, MPH Matthew T. Roe, MD, MHS Jyotsna Mulgund, MS Elizabeth
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
More informationJournal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationAcute Coronary Syndrome (ACS) Initial Evaluation and Management
Acute Coronary Syndrome (ACS) Initial Evaluation and Management Symptoms of Possible ACS Chest discomfort with or without radiation to the arm(s), jaw, or epigastrium Short of breath Weakness Diaphoresis
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationInstitutional Outcomes Report 2012Q2 Sample Hospital
Version 2.2 Institutional Outcomes Report 2012Q2 If User desires to publish or otherwise distribute or use, in whole or in part, any aggregate data or reports provided by ACCF, or produced in connection
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More informationConference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine
Conference Papers in Medicine, Article ID 719, pages http://dx.doi.org/1.1155/13/719 Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationLong-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA
Long-Term Management Of the ACS Patient: State-of-the-Art Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA Disclosures I have no disclosures. Case Study 45 y/o male admitted to
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 10, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 10, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.07.008 Outcomes
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationPragmatic Trial Design to Study Health Policy Interventions: Lessons Learned from ARTEMIS Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA
Pragmatic Trial Design to Study Health Policy Interventions: Lessons Learned from ARTEMIS Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA Associate Professor of Medicine, Duke University Director of Health Services
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More informationAwealth of research in acute coronary syndrome
CLINICAL TRIAL SUPPORT OF THE USE OF CRITICAL PATHWAYS IN IMPROVING PATIENT OUTCOMES Judy W. M. Cheng, PharmD, MPH, BCPS, FCCP * ABSTRACT Acute coronary syndrome (ACS) is a common condition encountered
More informationTicagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry Sukhdeep S. Basra, MD, MPH; Tracy Y. Wang, MD, MHS, MSc; DaJuanicia N. Simon, MS; Karen Chiswell,
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationSession 7: Cardiology I and II Answer Explanations
Session 7: Cardiology I and II Answer Explanations Cardiology I 1. Answer A: Intravenous heparin 4000-unit intravenous bolus, followed by a 1000-unit/hour continuous infusion. The NSTE-ACS guidelines recommend
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More information2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY
2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationBackground- Methods and Results- Conclusion-
Patterns of Use of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE Retrospective AMI Study
More informationChapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
More informationCurrent American College of Cardiology/American Heart
Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry Matthew W. Sherwood, MD; Stephen D. Wiviott, MD; S.
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More information